Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery

Parkinsonism and Related Disorders

Volumn 19, Issue 5, 2013, Pages 501-507

  Müller, Thomas ^a   Laar, Teus van ^b   Cornblath, David R ^c   Odin, Per ^d   Klostermann, Fabian ^e   Grandas, Francisco J ^f   Ebersbach, Georg ^g   Urban, Peter P ^h   Valldeoriola, Francesc ⁱ   Antonini, Angelo ^j  

^a ST JOSEPH KRANKENHAUS   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Klinikum Bremerhaven Reinkenheide   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g Klinikum Beelitz   (Germany)

^h ASKLEPIOS HOSPITAL BARMBEK   (Germany)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j IRCCS SAN CAMILLO HOSPITAL   (Italy)

more..

Author keywords

Homocysteine; Levodopa carbidopa intestinal gel; Parkinson's disease; Peripheral neuropathy; Vitamin B

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CYANOCOBALAMIN; DOPA DECARBOXYLASE INHIBITOR; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHYLMALONIC ACID; PARKIN; PLACEBO; PYRIDOXINE; TRIHEXYPHENIDYL;

CONTINUOUS INFUSION; CYANOCOBALAMIN DEFICIENCY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GUILLAIN BARRE SYNDROME; HUMAN; HYPERHOMOCYSTEINEMIA; PARKIN GENE; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PYRIDOXINE DEFICIENCY; REVIEW; SENSORIMOTOR NEUROPATHY; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; DRUG DELIVERY SYSTEMS; DUODENUM; HUMANS; LEVODOPA; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84875554066     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.02.006     Document Type: Review

References (64)

1. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002, 58:11-17.
2. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:983-995.
3. Nicolle E., Pollak P., Serre-Debeauvais F., Richard P., Gervason C.L., Broussolle E., et al. Pharmacokinetics of apomorphine in parkinsonian patients. Fundam Clin Pharmacol 1993, 7:245-252.
4. Antonini A., Isaias I.U., Rodolfi G.A. 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011, 258:579-585.
5. De Gaspari D., Siri C., Landi A., Cilia R., Bonetti A., Natuzzi F., et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. Neurol Neurosurg Psychiatry 2006, 77:450-453.
6. Antonini A. Continuous dopaminergic stimulation-from theory to clinical practice. Parkinsonism Relat Disord 2007, 13(Suppl.):S24-S28.
7. Merola A., Zibetti M., Angrisano S., Rizzi L., Lanotte M., Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011, 26:664-670.
8. Nyholm D., Nilsson Remahl A.I.M., Dizdar N., Constantinescu R., Holmberg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64:216-223.
9. Samanta J., Hauser R. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007, 8:657-664.
10. Nyholm D., Lewander T., Johansson A., Lewitt P.A., Lundqvist C., Aquilonius S.M. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008, 31:63-73.
11. Odin P., Wolters E., Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008, 29(Suppl. 5):S387-S388.
12. Capuano A., Rafaniello C., Potenza S., Morlino D., Parretta E., Rossi F. A signal from the Italian pharmacovigilance database: levodopa/carbidopa and polyneuropathy. Drug Saf 2010, 33:935-936.
13. Devos D., French DUODOPA Study Group Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009, 24:993-1000.
14. Nyholm D. Pharmacokinetic optimization in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006, 45:109-136.
15. Manca D., Cossu G., Murgia D., Molari A., Ferrigno P., Marcia E., et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009, 24:2293-2294.
16. Antonini A., Isaias I.U., Canesi M., Zibetti M., Mancini F., Manfredi L., et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007, 22:1145-1149.
17. Toth C., Brown M.S., Furtado S., Suchowersky O., Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008, 23:1850-1859.
18. Toth C., Breithaupt K., Ge S., Duan Y., Terris J.M., Thiessen A., et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010, 67:28-36.
19. Taly A.B., Muthane U.B. Involvement of peripheral nervous system in juvenile Parkinson's disease. Acta Neurol Scand 1992, 85:272-275.
20. Khan N.L., Graham E., Critchley P., Schrag A.E., Wood N.W., Lees A.J., et al. Parkin disease: a phenotypic study of a large case series. Brain 2003, 126:1279-1292.
21. Müller T., Renger K., Kuhn W. Levodopa associated homocysteine increase and sural axonal neurodegeneration. Arch Neurol 2004, 61:657-660.
22. Ohsawa Y., Kurokawa K., Sonoo M., Yamada H., Hemmi S., Iwatsuki K., et al. Reduced amplitude of the sural nerve sensory action potential in PARK2 patients. Neurology 2005, 65:459-462.
23. Nolano M., Provitera V., Estraneo A., Selim M.M., Caporaso G., Stancanelli A., et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain 2008, 131:1903-1911.
24. Chovancova Z., Kanovsky P., Dufek J., Nevrly M., Otruba P. Peripheral nerve involvement and severity of motor disorder in Parkinson's disease: a correlational study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009, 153:59-62.
25. Gondim Fde A., de Oliveira G.R., Peixoto A.A., Horta W.G. A case series of peripheral neuropathy in patients with Parkinson's disease. Ann Neurol 2010, 68:973-975.
26. Montastruc J.L., Danton A.C., Durrieu G., Lacroix I., Olivier P., Sommet A., et al. Neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view. Mov Disord 2010, 25:660-661.
27. Nolano M., Provitera V., Lanzillo B., Santoro L. Neuropathy in idiopathic Parkinson disease: an iatrogenic problem?. Ann Neurol 2011, 69:427-428.
28. Rajabally Y.A., Martey J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology 2011, 77:1947-1950.
29. Teodoro T., Pires R., Rosa M.M., Coelho M., Sampaio C., Ferreira J.J. Has " levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?. Mov Disord 2011, 26:1966-1967.
30. Santos-García D., de la Fuente-Fernández R., Valldeoriola F., Palasí A., Carrillo F., Grande M., et al. Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. J Neurol 2012, 259:1668-1672.
31. Gusmaroli G., Barbagli D., Ravagnani M., Mongiovetti M., Capone L., Tarletti R., et al. Axonal polyneuropathy during duodenal levodopa treatment in a woman with idiopathic Parkinson's disease. Mov Disord 2010, 25(Suppl. 3):S720.
32. Palasí A., Fábregues O., Hernández-Vara J., Seoane J.L., Gámez J., álvarez-Sabín J. Small fiber peripheral neuropathy presentation after starting treatment with continuous intraduodenal levodopa infusion in one patient with Parkinson disease. Poster presentation at: 7th international congress on mental dysfunction and other non-motor features in Parkinson's disease December 9-12, 2010, Barcelona, Spain.
33. Urban P.P., Wellach I., Faiss S., Layer P., Rosenkranz T., Knop K., et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010, 25:1748-1752.
34. Valldeoriola F., Cámara A. Intraduodenal infusion of levodopa. Rev Neurol 2010, 51:41-48.
35. Klostermann F., Jugel C., Müller T., Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012, 119:369-372.
36. Meppelink A.M., Nyman R., van Laar T., Drent M., Prins T., Leenders K.L. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Mov Disord 2011, 26:331-334.
37. Santos-García D., Macías M., Llaneza M., Grande M., de la Fuente-Fernández R. Serum vitamin B(12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion. Mov Disord 2011, 26:558-559.
38. Onofrj M., Bonanni L., Cossu G., Manca D., Stocchi F., Thomas A. Emergencies in parkinsonism, akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Relat Disord 2009, 15(Suppl. 3):S233-S236.
39. Postuma R.B., Lang A.E. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?. Neurology 2004, 63:886-891.
40. O'Suilleabhain P., Diaz-Arrastia R. Levodopa elevates homocysteine. Is this a problem?. Arch Neurol 2004, 61:633-634.
41. Allain P., Le Bouil A., Cordillet E., Le Quay L., Bagheri H., Montastruc J.L. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995, 16:527-529.
42. Kuhn W., Roebroek R., Blom H., van Oppenraaij D., Przuntek H., Kretschmer A., et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998, 40:225-227.
43. Müller T., Werne B., Fowler B., Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 1999, 354:126-127.
44. Yasui K., Kowa H., Nakaso K., Takeshima T., Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000, 55:437-440.
45. Kuhn W., Hummel T., Woitalla D., Müller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2001, 56:281-282.
46. Müller T., Woitalla D., Hauptmann B., Fowler B., Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001, 308:54-56.
47. Miller J.W., Selhub J., Nadeau M.R., Thomas C.A., Feldman R.G., Wolf P.A. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003, 60:1125-1129.
48. Müller T., Woitalla D., Kuhn W. Benefit of folic acid supplementation in parkinsonian patients treated with levodopa. J Neurol Neurosurg Psychiatry 2003, 74:549.
49. Toth C., Suchowersky O., Zochodne D. Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view. Mov Disord 2010, 25:525.
50. Duan W., Ladenheim B., Cutler R.G., Kruman, Cadet J.L., Mattson M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002, 80:101-110.
51. Miller J.W., Shukitt-Hale B., Villalobos-Molina R., Nadeau M.R., Selhub J., Joseph J.A. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997, 20:55-66.
52. Chung K.K., Dawson V.L., Dawson T.M. S-nitrosylation in Parkinson's disease and related neurodegenerative disorders. Methods Enzymol 2005, 396:139-150.
53. Müller T. Role of homocysteine in the treatment of Parkinson's disease. Expert Rev Neurother 2008, 8:957-967.
54. Cacciapuoti F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 2011, 32:82-88.
55. Müller T. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. Int Rev Neurobiol 2010, 95:49-71.
56. Müller T., Kuhn W. Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov Disord 2009, 24:929-932.
57. Heiser P., Teepker M., Möller J.C., Theisen F.M., Friedel S., Hebebrand J., et al. Neuropathy due to hypovitaminosis following excessive weight loss. J Am Acad Child Adolesc Psychiatry 2004, 43:928-929.
58. Weber G.A., Sloan P., Davies D. Nutritionally induced peripheral neuropathies. Clin Podiatr Med Surg 1990, 7:107-128.
59. Centers for Disease Control and Prevention. Managing patients with evidence of vitamin B12 deficiency. Last updated 29.06.09. [accessed 12.03.12]. http://www.cdc.gov/ncbddd/b12/patients.html.
60. 12 deficiency. Dtsch Arztebl Int 2008, 105:680-685.
61. Butler C.C., Vidal-Alaball J., Cannings-John R., McCaddon A., Hood K., Papaioannou A., et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Pract 2006, 23:279-285.
62. Vidal-Alaball J., Butler C.C., Cannings-John R., Goringe A., Hood K., McCaddon A., et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev 2005, 3:CD004655.
63. Müller T., Kuhn W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol 2006, 62:447-450.
64. Nyholm D., Johansson A., Lennernäs H., Askmark H. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol 2012, 19:820-826.